---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-21-000481"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T13:00:10.122829+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma awarded USPTO patent for NR2F6-silenced cord blood killer cell cancer therapy

## Summary
- USPTO issued Patent No. 11,141,471 on Oct 12, 2021, covering universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells.
- Invention targets NR2F6 silencing or gene editing in cord blood cells to produce potentiated killer cells for anticancer therapy.
- Patent includes compositions of matter, cells, and treatment protocols for inducing anticancer immune responses.
- Allogeneic cord blood killer cells are administered to initiate antitumor immune responses, first allogeneic then endogenous.

## SEC filing metadata
- accession: 0001607062-21-000481
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000481/0001607062-21-000481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000481/rgbp110321form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-21-000481
- JSON: https://secwatch.observer/filing/0001607062-21-000481.json
- Plain text: https://secwatch.observer/filing/0001607062-21-000481.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.